A TCA cycle intermediate that serves as a cofactor for epigenetic enzymes. The TruAge trial reported biological age reduction — here is what that claim means and how strong the evidence actually is.
Alpha-ketoglutarate is not an exotic supplement — it is a central metabolite in the TCA cycle that every cell in the body produces. What makes it interesting for longevity is its role as a required cofactor for two families of epigenetic enzymes.
TET enzymes, which demethylate DNA, and KDM histone demethylases, which regulate chromatin accessibility, both require AKG as a co-substrate. In aging tissue, AKG levels decline — and because epigenetic dysregulation is one of the twelve hallmarks of aging, the hypothesis that restoring AKG could partially reverse epigenetic aging has mechanistic coherence.
Animal data reinforces the hypothesis: AKG supplementation extends lifespan in C. elegans and mice, and the most cited mouse study showed median lifespan extension of roughly 12% in females and 10% in males when supplementation began in mid-life. The question is whether this translates to humans.
The most-cited human evidence is the TruAge trial, published in Aging in 2023. It is frequently cited by supplement companies as evidence of "8 years of biological age reduction." The actual study design requires careful reading.
The absence of a control group is the critical limitation. Epigenetic clocks can shift for many reasons — including regression to the mean, seasonal variation, and technical batch effects in the methylation assay. Without a placebo arm, it is impossible to know how much of the reported shift is attributable to AKG versus other factors.
This is an important question that the longevity supplement industry frequently elides. Epigenetic clocks — Horvath, GrimAge, PhenoAge — are trained on population data to predict biological age and, in some cases, mortality risk at the population level. They have genuine predictive value in epidemiological settings.
What they do not do is provide validated individual-level mortality predictions, and more importantly, it has not been demonstrated that interventions which reduce epigenetic clock scores thereby reduce mortality. The clock could shift without affecting underlying aging biology, or the shift could reflect a true biological change. Current evidence cannot distinguish these possibilities.
AKG has a mechanistically coherent longevity hypothesis and supportive animal data. The human evidence is limited to one uncontrolled trial using a surrogate endpoint whose clinical validity as an individual predictor remains unestablished.
The evidence tier is Emerging — appropriate given the animal data and mechanistic case, but the human longevity evidence is among the weaker in the current pharmacopeia. A placebo-controlled RCT using GrimAge or PhenoAge as endpoints, with longer follow-up, is what the field needs before AKG can move to Moderate tier.
This information is provided for educational reference only and does not constitute medical advice or a treatment recommendation.